What is Immunos Therapeutics?
Founded in 2014, ImmunOs Therapeutics AG operates at the intersection of advanced protein engineering and immunology. The company specializes in the discovery and development of novel human immunomodulatory proteins that serve as critical regulators of the immune system. By targeting both innate and adaptive immune pathways, ImmunOs aims to create therapeutic solutions that are more effective and precise than current standards of care. Its strategic focus on high-impact, clinical-stage assets has established the firm as a key player in the European biotech ecosystem, particularly within the competitive landscape of Swiss-based life science innovation.
How much funding has Immunos Therapeutics raised?
Immunos Therapeutics has raised a total of $99.2M across 3 funding rounds:
Series A
$15.2M
Series B
$73M
Series C
$11M
Series A (2019): $15.2M with participation from Schroder Adveq, Wille Finance AG, BioMedPartners, Redalpine, BERNINA BioInvest Ltd, and Pfizer Ventures
Series B (2022): $73M, investors not publicly disclosed
Series C (2024): $11M supported by BioMedPartners, Gimv, Mission BioCapital, and Pfizer
Key Investors in Immunos Therapeutics
BioMedPartners
An independent venture capital firm based in Basel, Switzerland, specializing in early-stage biotech companies with highly innovative assets and technology platforms.
Gimv
A European investment company that partners with mid-market businesses across five strategic sectors, including Life Sciences, to foster sustainable long-term growth.
Mission BioCapital
A venture capital firm providing early-stage capital and mentorship to life science entrepreneurs, focusing on accelerating the development of scientific breakthroughs.
What's next for Immunos Therapeutics?
With the successful completion of this major enterprise-level funding round, ImmunOs Therapeutics is poised to transition into a more mature phase of clinical execution. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through rigorous clinical trials, while simultaneously expanding its research capabilities to explore new therapeutic targets. As the company scales, the focus will remain on maintaining its technological edge in protein discovery and fostering partnerships that can facilitate the eventual commercialization of its pipeline. The continued involvement of top-tier venture capital firms and strategic biopharmaceutical partners underscores the long-term potential of the ImmunOs platform to deliver transformative medical breakthroughs.
See full Immunos Therapeutics company page
